{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.26","value":"-0.4"},{"groupId":"OG001","spread":"0.26","value":"-1.2"},{"groupId":"OG002","spread":"0.27","value":"-1.0"}]}],"title":"Change from Baseline at Week 4 [N=61; 62; 58]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.27","value":"-0.9"},{"groupId":"OG001","spread":"0.26","value":"-1.7"},{"groupId":"OG002","spread":"0.28","value":"-1.7"}]}],"title":"Change from Baseline at Week 8 [N=60; 63; 57]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.30","value":"-1.1"},{"groupId":"OG001","spread":"0.29","value":"-2.1"},{"groupId":"OG002","spread":"0.32","value":"-1.9"}]}],"title":"Change from Baseline at Week 12 [N=59; 61; 53]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.29","value":"-1.1"},{"groupId":"OG001","spread":"0.28","value":"-2.0"},{"groupId":"OG002","spread":"0.30","value":"-1.9"}]}],"title":"Change from Baseline at EOT [N=62; 63; 58]"}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"58"}],"units":"Participants"}],"description":"Participants were asked to rate how much their urinary symptoms interfered overall with their everyday life on a scale from 0 (not at all) to 10 (a great deal).\n\nLeast squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.","dispersionType":"Standard Error","groups":[{"description":"Participants received matching mirabegron placebo tablets orally once daily for 12 weeks.","id":"OG000","title":"Placebo"},{"description":"Participants received 50 mg mirabegron tablets orally once daily for 12 weeks.","id":"OG001","title":"Mirabegron 50 mg"},{"description":"Participants received 100 mg mirabegron tablets orally once daily for 12 weeks.","id":"OG002","title":"Mirabegron 100 mg"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The Full Analysis Set included all patients who received at least 1 dose of double-blind study drug \\& had both Qmax \\& PdetQmax measurements at baseline \\& 1 or both at any postbaseline on-treatment visit. End of treatment (EOT) includes the last on-treatment assessment for patients who didn't complete Week 12; N is the number of patients included.","reportingStatus":"POSTED","timeFrame":"Baseline and Weeks 4, 8 and 12","title":"Change From Baseline to Weeks 4, 8, 12 and End of Treatment in International Consultation on Incontinence Questionnaire - Lower Urinary Tract Symptom Quality of Life (ICIQ-LUTSqol) Overall Symptom Interference of Life Score","type":"SECONDARY","unitOfMeasure":"scores on a scale"}